SANGAMO THERAPEUTICS, INC

SGMOSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1001233

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$176.2M	$110.7M	$118.2M	$102.4M	$84.5M
Research and Development Expense	$234.1M	$230.8M	$180.6M	$145.9M	$114.9M
Operating Expenses	$450.2M	$294.0M	$247.7M	$207.6M	$161.6M
Operating Income (Loss)	-$274.0M	-$183.3M	-$129.6M	-$105.2M	-$77.2M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$262.9M	-$178.0M	-$120.8M	-$95.4M	-$68.9M
Income Tax Expense (Benefit)	-$5.1M	$306.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$165.3M	$562.5M	$721.9M	$938.5M	$637.5M
Assets, Current	$94.3M	$300.3M	$398.8M	$659.7M	$405.5M
Cash and Cash Equivalents, at Carrying Value	$45.2M	$100.4M	$178.9M	$131.3M	$80.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$923.0K	$3.7M	$6.0M	$5.2M	$36.9M
Liabilities	$82.4M	$267.6M	$346.6M	$441.2M	$204.8M
Liabilities, Current	$47.7M	$111.7M	$127.9M	$143.5M	$69.9M
Accounts Payable, Current	$15.3M	$22.4M	$9.8M	$12.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$224.8M	-$233.3M	$169.9M	-$144.4M	$36.5M
Net Cash Provided by (Used in) Investing Activities	$153.5M	$248.2M	-$271.6M	-$59.8M	-$178.1M
Net Cash Provided by (Used in) Financing Activities	$14.6M	$32.9M	$153.1M	$142.0M	$231.7M
Payments to Acquire Property, Plant, and Equipment	$21.2M	$23.3M	$14.7M	$20.7M	$43.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)